ClinicalTrials.gg
CompletedNCT05335356STELLAR-2Updated Sep 12, 2025Results posted

Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of Stelara and Bmab1200 in Moderate to Severe Chronic Plaque Psoriasis, sponsored by Biocon Biologics UK Ltd. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Biocon Biologics UK Ltd · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
384
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 766 studies in Psoriasis with a site in United States — 57 open to participants now, 88 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
118th of 675
384 · median 77
Started
2022
with 36 others
Phase 3
188 of 766
6 open now
Registered
647th of 766
by date

Among the 766 studies in Psoriasis with a site in United States, this one is the 118th largest by enrollment of the 675 interventional ones that give a count, is one of 37 that started in 2022, is one of 188 in phase 3, and was the 647th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

57 of the 766 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 766 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, active-controlled, parallel-group, multicenter study designed to compare the efficacy, safety, immunogenicity, and PK(Pharmacokinetic) of Bmab 1200 with Stelara in adult patients with moderate to severe chronic plaque psoriasis.

Read the detailed description

Approximately 384 patients with moderate to severe plaque psoriasis will be enrolled and randomly assigned to one of the 2 treatment groups in a 1:1 ratio (192 patients in the Bmab 1200 group and 192 patients in the Stelara group). Patients who are diagnosed as moderate to severe chronic plaque psoriasis for at least 6 months and are candidate for systemic therapy or phototherapy at the time of the screening visit will be enrolled. The study is planned to be conducted in Europe and North America across approximately 48 sites in 5 countries. The study will be conducted in an outpatient setting, and the participation for each patient will consist of a screening period (up to 4 weeks/28 days) and a double-blind, active-controlled treatment period (52 weeks) with a rerandomization step for switching therapy (Bmab 1200 with Stelara ) before Week 16 dosing. The treatment period before the switch is TP1(Treatment Period1) and post switch is TP2(Treatment Period 2) (from Week 16 dosing to prior to Week 28 dosing) and TP3 (Treatment Period3)(from Week 28 dosing to Week 52). The total duration of the study (excluding the screening period) will be 52 weeks.

03

Conditions studied

  • Moderate to Severe Chronic Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is willing and able to provide form (ICF), able to follow study instructions, and comply with the protocol requirements as per the investigator's opinion.
  2. Patient is aged 18 to 80 years, both inclusive, and weighing \<130 kg at the time of the screening visit.
  3. Patient has a diagnosis of chronic plaque psoriasis for at least 6 months and is a candidate for systemic therapy or phototherapy at the time of the screening visit.
  4. Patient with moderate to severe chronic plaque psoriasis as defined by BSA (Body surface area)involvement

    • 10%, PASI score ≥12, and sPGA ≥3 at the screening and baseline visits.
  5. Patient has stable disease for at least 2 months before the baseline visit (ie, without changes in the investigator's opinion).
  6. Patient has adequate renal and hepatic function at the screening
  7. Women of must have a negative serum pregnancy test during screening and a negative urine pregnancy test at baseline. A female patient is considered not of childbearing potential when or surgically sterilized
  8. Women of childbearing potential and male patients with a female partner of childbearing potential must be willing to use highly effective precautions.

Exclusion criteria

Exclusion Criteria:

  1. Patient has nonplaque psoriasis, such as erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, other skin conditions (eg, eczema), other current or chronic systemic or inflammatory disease at the time of screening visit that would interfere with the evaluation of the effect of the study treatment on psoriasis. Patients with concurrent psoriatic arthritis will be allowed to participate.
  2. Patient who has a current or past history of any of the following infections:

    1. Current or past history of congenital or acquired immunodeficiency or patient is positive for the (HIV) antibodies (HIV-1 or HIV-2) at screening.
    2. Patient has current infection with virus (HBV) or virus (HCV) as per serological tests at screening.

      • For HBV, patients who test positive to hepatitis B surface antigen (HBsAg) will be excluded. Patients who test positive to hepatitis B core antibody (HBcAb) only (HBsAg negative), may be enrolled if they also test positive to hepatitis B surface antibody (HBsAb).
      • For HCV, patient who test positive to HCV antibody will be excluded unless they test negative for HCV RNA.
    3. Presence of active infection at screening or history of infection requiring intravenous antibiotics and/or hospitalization ≤8 weeks before baseline visit, or oral/intramuscular antibiotics ≤4 weeks before baseline visit, or topical antibiotics ≤2 weeks before baseline visit. Minor localized fungal infections or topical antibiotics for facial acne may be allowed.
    4. Any recurrent bacterial, fungal, opportunistic or viral infection including recurrent/disseminated herpes zoster that, based on the investigator´s clinical assessment, causes a safety risk and makes the patient unsuitable for the study.
    5. History of invasive/systemic fungal infection (eg, histoplasmosis) or nontubercular mycobacterial infection.
  3. Patient meeting any of the following tuberculosis (TB)-related conditions:

    1. Patient who has current or history of active TB.
    2. Patient who has signs or symptoms suggestive of active TB upon medical history or physical examination including chest radiography at screening. If a chest radiography performed within the past 3 months before screening is available, it does not need to be repeated at screening.
    3. Patients with current latent TB (defined as a positive result of interferon-γ release assay [IGRA] with a negative examination of chest radiography [posterior-anterior and lateral views, or per country regulations where applicable] and absence of symptoms). Patients with positive IGRA (Interferon Gamma Release Assay) may be enrolled if they have documentation of completed appropriate country-specific TB prophylaxis within the past 5 years or have received at least 1 month of country-specific TB prophylaxis before the baseline visit and are willing to complete its entire course, and do not have other risk factors, radiologic findings, or physical evidence supporting latent or active TB. If a patient's initial IGRA test result is indeterminate, the test can be repeated once. If the test result is again indeterminate, the patient will be excluded from the study.
    4. Patient who has had exposure to a person with active TB, such as first-degree family members or coworkers within 16 weeks before the baseline visit.
  4. Patient has an underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic including central nervous system demyelinating disease, endocrine, cardiac, infection, or gastrointestinal) which, in the opinion of the investigator, significantly immune-compromises the patient and/or places the patient at unacceptable risk for receiving an immunomodulatory therapy.
  5. Patient had a major surgical intervention within 12 weeks of the baseline or planned major surgery during the study period.
  6. Patient who has prior exposure to more than 1 biologic agent for the treatment of psoriasis or psoriatic arthritis.
  7. Patient who has received or plans to receive any of the prohibited medications or treatment that could affect psoriasis:
  8. Patient has received a live or within 4 weeks before the baseline visit. Patient must agree not to receive a live or live-attenuated vaccine during the study and up to 15 weeks after the last dose of the study treatment.
  9. Patient who has had Bacillus Calmette-Guérin (BCG) vaccination within 1 year before the baseline visit. Patients must agree not to receive a BCG vaccination during the study and at least 1 year after the last dose of the study treatment.
  10. Have a transplanted organ/tissue or stem cell transplantation.
  11. TP3 specific criteria:

    1. Patient is willing and able to provide revised form (ICF), able to follow study instructions, and comply with the protocol requirements as per the investigator's opinion
    2. Patient has not developed any condition/ or met study discontinuation or treatment
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
384 participants (actual)

Study arms

  • Experimental
    Bmab1200

    Bmab 1200 45 mg Bmab 1200 90 mg

    Biological: Bmab1200

  • Active comparator
    Stelara

    Stelara 45 mg Stelara 90 mg

    Biological: Stelara

Interventions

  • BiologicalUstekinumabStudies of UstekinumabUstekinumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    45 mg , 90 mg at Week 0, 4, 16, 28 and 40;During the study after receiving 2 doses , before dosing at Week 16 patients were re-randomised in a 1:1 ratio to receive either Bmab 1200 or Stelara .

  • BiologicalBmab1200

    45 mg , 90 mg at Week 0, 4, 16, 28 and 40

06

What researchers measure

Primary outcomes

  1. Psoriasis Area and Severity Index (PASI)

    Percentage change from baseline in the Psoriasis Area and Severity Index score at Week 12

    Time frame: Baseline to Week 12

Secondary outcomes

  1. PASI Score

    Percentage change from baseline in the PASI score at Baseline through Week 28. PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage, plaque appearance, their response to therapy. 4 regions- head, upper limbs, trunk, and lower limbs are assessed separately for erythema, induration/thickness, and scaling. Degree of involvement is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement) for each region. Total score (sum of erythema, thickness, and scaling) is multiplied by the degree of involvement for each body region and then multiplied by constant. Sum of all lesion scores can range from 0 (no disease) to 72 (maximal disease), with the higher score indicating more severe disease. Change from baseline in PASI score indicates response to therapy. PASI 50 means ≥50% reduction from baseline in the PASI score

    Time frame: Baseline through Week 28

  2. PASI Improvement

    PASI improvement of ≥50% relative to baseline (PASI 50), PASI improvement of ≥75% relative to baseline (PASI 75), and PASI improvement of ≥90% relative to Baseline through Week 28 and 52 PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage, plaque appearance, their response to therapy. 4 regions- head, upper limbs, trunk, and lower limbs are assessed separately for erythema, induration/thickness, and scaling. Degree of involvement is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement) for each region. Total score (sum of erythema, thickness, and scaling) is multiplied by the degree of involvement for each body region and then multiplied by constant. Sum of all lesion scores can range from 0 (no disease) to 72 (maximal disease), with the higher score indicating more severe disease. Change from baseline in PASI score indicates response to therapy. PASI 50 means ≥50% reduction from baseline in the PASI score

    Time frame: Baseline through Week 28

  3. Static Physician's Global Assessment (sPGA)

    Change from Baseline in sPGA During TP2. The sPGA is a quantitative rating score of the patient's psoriasis based on physician's assessment at a given time point according to the following categories: induration, erythema, and scaling. The sPGA is a 6-point scale and patient's psoriasis is graded as clear (0), minimal (1), mild (2), moderate (3), marked (4), severe (5). The sum of the scores for induration, erythema, and scaling will be divided by 3 to obtain a final sPGA score. lower score indicates better disease status

    Time frame: Baseline through Week 28

  4. Affected Body Surface Area

    Change from baseline in affected body surface area at Weeks 28 Total % BSA afflicted by psoriasis is estimated using a handprint of the patient at each visit . The entire palmar surface of the patient's handprint is assumed to correspond to approximately 1% of total BSA. Reduction in BSA indicates improvement

    Time frame: Baseline through Week 28

  5. Dermatology Life Quality Index Scores

    Change from baseline in quality of life as measured by Dermatology Life Quality Index scores at Weeks 28 It is a 10-item patient-reported outcome questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Nine of the 10 questions have response categories including "not relevant" (score of 0), "not at all" (score of 0), "a little" (score of 1), "a lot" (score of 2) and "very much" (score of 3); Question 7 is a "yes"/ "no" question where "yes" is scored as 3. Eight items also have a "Not relevant" option scored "0," which indicates no problems. Total scores range from 0 to 30 (less to more impairment) and a 5-point change from baseline is considered a clinically important difference.

    Time frame: Baseline through Week 28

  6. Dermatology Life Quality Index Scores

    Change from baseline in quality of life as measured by Dermatology Life Quality Index scores at Weeks 52 It is a 10-item patient-reported outcome questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Nine of the 10 questions have response categories including "not relevant" (score of 0), "not at all" (score of 0), "a little" (score of 1), "a lot" (score of 2) and "very much" (score of 3); Question 7 is a "yes"/ "no" question where "yes" is scored as 3. Eight items also have a "Not relevant" option scored "0," which indicates no problems. Total scores range from 0 to 30 (less to more impairment) and a 5-point change from baseline is considered a clinically important difference.

    Time frame: Baseline through Week 52

  7. Static Physician's Global Assessment (sPGA)

    Change in Static Physician's Global Assessment (sPGA) at Weeks 52 The sPGA is a quantitative rating score of the patient's psoriasis based on physician's assessment at a given time point according to the following categories: induration, erythema, and scaling. The sPGA is a 6-point scale and patient's psoriasis is graded as clear (0), minimal (1), mild (2), moderate (3), marked (4), severe (5). The sum of the scores for induration, erythema, and scaling will be divided by 3 to obtain a final sPGA score. lower score indicates better disease status

    Time frame: Baseline through Week 52

  8. Affected Body Surface Area

    Change from baseline in affected body surface area at Weeks 52 Total % BSA afflicted by psoriasis is estimated using a handprint of the patient at each visit . The entire palmar surface of the patient's handprint is assumed to correspond to approximately 1% of total BSA. Reduction in BSA indicates improvement

    Time frame: Baseline through Week 52

  9. PASI Improvement

    PASI improvement of ≥50% relative to baseline (PASI 50), PASI improvement of ≥75% relative to baseline (PASI 75), and PASI improvement of ≥90% relative to Week 52

    Time frame: Baseline through week 52

  10. PASI Score

    Percentage change from baseline in the PASI score at Baseline through Week 52. The PASI (Psoriasis Area and Severity Index) is a score from 0 to 72 that measures psoriasis severity based on lesion redness, thickness, scaling, and body area affected. The body is divided into four regions, each scored separately. Scores are calculated using severity and area involvement, and are used to assess treatment response (e.g., PASI 50 = 50% improvement).

    Time frame: Baseline through Week 52

Other outcomes

  1. Safety:-Treatment-emergent Adverse Events Including Adverse Events of Special Interest and Adverse Reactions During the Treatment Period

    Time frame: Baseline to Week 52

  2. Safety:- Injection-site Reactions

    Injection-site reactions at Day 1, Week 4, Week 16, and throughout the study

    Time frame: Baseline through Week 28 and 52

  3. Safety:- Hypersensitivity

    Hypersensitivity at Day 1, Week 4, Week 16, and throughout the study

    Time frame: Baseline through Week 52

  4. Immunogenicity:-Developing Antidrug Antibodies

    Proportion of patients developing antidrug antibodies

    Time frame: Baseline through Week 28

  5. Immunogenicity:-Developing Antidrug Antibodies

    Proportion of patients developing antidrug antibodies

    Time frame: Postdosing Week 52

  6. Developing Neutralizing Antibodies

    Proportion of patients neutralizing antibodies

    Time frame: Baseline through Week 28

  7. Developing Neutralizing Antibodies

    Proportion of patients neutralizing antibodies

    Time frame: Postdosing Week 52

  8. Pharmacokinetic:-Serum Concentrations

    Serum concentrations of ustekinumab

    Time frame: Postdosing on Week 28

  9. Pharmacokinetic:-Serum Concentrations

    Serum concentrations of Ustekinumab

    Time frame: Postdosing on Week 52

07

Results

Posted Sep 12, 2025

Participant flow

The study was conducted in Europe and North America and enrolled patients across 41 sites in 5 countries.

Treatment Period 1 (Baseline to Week 16)
Participant flow — Treatment Period 1 (Baseline to Week 16)
MilestoneBmab1200StelaraBmab 1200- Bmab 1200Stelara-StelaraStelara-Bmab 1200Bmab 1200/Bmab 1200Stelara/StelaraStelara/Bmab 1200
Started191193000000
Completed190192000000
Not completed11000000
Treatment Period 2 (Week 16 to Week 28)
Participant flow — Treatment Period 2 (Week 16 to Week 28)
MilestoneBmab1200StelaraBmab 1200- Bmab 1200Stelara-StelaraStelara-Bmab 1200Bmab 1200/Bmab 1200Stelara/StelaraStelara/Bmab 1200
Started001859492000
Completed001718786000
Not completed001476000
Treatment Period 3 (Week 28 to Week 52)
Participant flow — Treatment Period 3 (Week 28 to Week 52)
MilestoneBmab1200StelaraBmab 1200- Bmab 1200Stelara-StelaraStelara-Bmab 1200Bmab 1200/Bmab 1200Stelara/StelaraStelara/Bmab 1200
Started000001688184
Completed000001637982
Not completed00000522

Outcome measures

PrimaryPsoriasis Area and Severity Index (PASI)

Percentage change from baseline in the Psoriasis Area and Severity Index score at Week 12

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Percentage change from baseline
Psoriasis Area and Severity Index (PASI)
Percentage change from baselineBmab1200Stelara
Psoriasis Area and Severity Index (PASI)-79.87 ± 2.818-80.55 ± 2.783
SecondaryPASI Score

Percentage change from baseline in the PASI score at Baseline through Week 28. PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage, plaque appearance, their response to therapy. 4 regions- head, upper limbs, trunk, and lower limbs are assessed separately for erythema, induration/thickness, and scaling. Degree of involvement is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement) for each region. Total score (sum of erythema, thickness, and scaling) is multiplied by the degree of involvement for each body region and then multiplied by constant. Sum of all lesion scores can range from 0 (no disease) to 72 (maximal disease), with the higher score indicating more severe disease. Change from baseline in PASI score indicates response to therapy. PASI 50 means ≥50% reduction from baseline in the PASI score

Time frame:
Baseline through Week 28
Reported as:
Mean · Percentage change from Baseline in Score
PASI Score
Percentage change from Baseline in ScoreBmab1200StelaraStelara-Bmab 1200
PASI Score-95.50 ± 6.068-96.01 ± 6.461-95.44 ± 7.321
SecondaryPASI Improvement

PASI improvement of ≥50% relative to baseline (PASI 50), PASI improvement of ≥75% relative to baseline (PASI 75), and PASI improvement of ≥90% relative to Baseline through Week 28 and 52 PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage, plaque appearance, their response to therapy. 4 regions- head, upper limbs, trunk, and lower limbs are assessed separately for erythema, induration/thickness, and scaling. Degree of involvement is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement) for each region. Total score (sum of erythema, thickness, and scaling) is multiplied by the degree of involvement for each body region and then multiplied by constant. Sum of all lesion scores can range from 0 (no disease) to 72 (maximal disease), with the higher score indicating more severe disease. Change from baseline in PASI score indicates response to therapy. PASI 50 means ≥50% reduction from baseline in the PASI score

Time frame:
Baseline through Week 28
Reported as:
Count of participants · Participants
PASI Improvement
ParticipantsBmab1200Stelara-StelaraStelara-Bmab 1200
PASI 501688084
PASI 751687983
PASI 901407067
SecondaryStatic Physician's Global Assessment (sPGA)

Change from Baseline in sPGA During TP2. The sPGA is a quantitative rating score of the patient's psoriasis based on physician's assessment at a given time point according to the following categories: induration, erythema, and scaling. The sPGA is a 6-point scale and patient's psoriasis is graded as clear (0), minimal (1), mild (2), moderate (3), marked (4), severe (5). The sum of the scores for induration, erythema, and scaling will be divided by 3 to obtain a final sPGA score. lower score indicates better disease status

Time frame:
Baseline through Week 28
Reported as:
Mean · score on a scale
Static Physician's Global Assessment (sPGA)
score on a scaleBmab1200StelaraStelara-Bmab 1200
Static Physician's Global Assessment (sPGA)-3.0 ± 1.21-2.9 ± 1.21-2.8 ± 1.28
SecondaryAffected Body Surface Area

Change from baseline in affected body surface area at Weeks 28 Total % BSA afflicted by psoriasis is estimated using a handprint of the patient at each visit . The entire palmar surface of the patient's handprint is assumed to correspond to approximately 1% of total BSA. Reduction in BSA indicates improvement

Time frame:
Baseline through Week 28
Reported as:
Mean · Percentage of total body surface area
Affected Body Surface Area
Percentage of total body surface areaBmab1200StelaraStelara-Bmab 1200
Affected Body Surface Area-26.52 ± 15.152-25.91 ± 13.323-28.33 ± 17.251
SecondaryDermatology Life Quality Index Scores

Change from baseline in quality of life as measured by Dermatology Life Quality Index scores at Weeks 28 It is a 10-item patient-reported outcome questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Nine of the 10 questions have response categories including "not relevant" (score of 0), "not at all" (score of 0), "a little" (score of 1), "a lot" (score of 2) and "very much" (score of 3); Question 7 is a "yes"/ "no" question where "yes" is scored as 3. Eight items also have a "Not relevant" option scored "0," which indicates no problems. Total scores range from 0 to 30 (less to more impairment) and a 5-point change from baseline is considered a clinically important difference.

Time frame:
Baseline through Week 28
Reported as:
Mean · score on a scale
Dermatology Life Quality Index Scores
score on a scaleBmab1200StelaraStelara-Bmab 1200
Dermatology Life Quality Index Scores-12.2 ± 6.84-10.5 ± 6.74-12.2 ± 7.08
SecondaryDermatology Life Quality Index Scores

Change from baseline in quality of life as measured by Dermatology Life Quality Index scores at Weeks 52 It is a 10-item patient-reported outcome questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Nine of the 10 questions have response categories including "not relevant" (score of 0), "not at all" (score of 0), "a little" (score of 1), "a lot" (score of 2) and "very much" (score of 3); Question 7 is a "yes"/ "no" question where "yes" is scored as 3. Eight items also have a "Not relevant" option scored "0," which indicates no problems. Total scores range from 0 to 30 (less to more impairment) and a 5-point change from baseline is considered a clinically important difference.

Time frame:
Baseline through Week 52
Reported as:
Mean · score on a scale
Dermatology Life Quality Index Scores
score on a scaleBmab1200StelaraStelara-Bmab 1200
Dermatology Life Quality Index Scores-12.8 ± 6.73-11.5 ± 6.35-12.7 ± 6.98
SecondaryStatic Physician's Global Assessment (sPGA)

Change in Static Physician's Global Assessment (sPGA) at Weeks 52 The sPGA is a quantitative rating score of the patient's psoriasis based on physician's assessment at a given time point according to the following categories: induration, erythema, and scaling. The sPGA is a 6-point scale and patient's psoriasis is graded as clear (0), minimal (1), mild (2), moderate (3), marked (4), severe (5). The sum of the scores for induration, erythema, and scaling will be divided by 3 to obtain a final sPGA score. lower score indicates better disease status

Time frame:
Baseline through Week 52
Reported as:
Mean · score on a scale
Static Physician's Global Assessment (sPGA)
score on a scaleBmab1200StelaraStelara-Bmab 1200
Static Physician's Global Assessment (sPGA)-3.1 ± 1.21-3.0 ± 1.29-2.9 ± 1.20
SecondaryAffected Body Surface Area

Change from baseline in affected body surface area at Weeks 52 Total % BSA afflicted by psoriasis is estimated using a handprint of the patient at each visit . The entire palmar surface of the patient's handprint is assumed to correspond to approximately 1% of total BSA. Reduction in BSA indicates improvement

Time frame:
Baseline through Week 52
Reported as:
Mean · Change from Baseline in %BSA
Affected Body Surface Area
Change from Baseline in %BSABmab1200StelaraStelara-Bmab 1200
Affected Body Surface Area-27.42 ± 15.119-26.50 ± 13.160-28.90 ± 17.560
SecondaryPASI Improvement

PASI improvement of ≥50% relative to baseline (PASI 50), PASI improvement of ≥75% relative to baseline (PASI 75), and PASI improvement of ≥90% relative to Week 52

Time frame:
Baseline through week 52
Reported as:
Count of participants · Participants
PASI Improvement
ParticipantsBmab1200StelaraStelara-Bmab 1200
PASI 501638083
PASI 751598081
PASI 901337063
Other pre-specifiedSafety:-Treatment-emergent Adverse Events Including Adverse Events of Special Interest and Adverse Reactions During the Treatment Period
Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Safety:-Treatment-emergent Adverse Events Including Adverse Events of Special Interest and Adverse Reactions During the Treatment Period
ParticipantsBmab1200StelaraStelara-Bmab1200
Endometrial adenocarcinoma100
Squamous cell carcinoma of the tongue100
Angioedema010
Rash maculo-papular010
Abdominal pain100
Jaundice cholestatic100
Alcohol poisoning010
Other pre-specifiedSafety:- Injection-site Reactions

Injection-site reactions at Day 1, Week 4, Week 16, and throughout the study

Time frame:
Baseline through Week 28 and 52

No measurements were reported for this outcome.

Other pre-specifiedSafety:- Hypersensitivity

Hypersensitivity at Day 1, Week 4, Week 16, and throughout the study

Time frame:
Baseline through Week 52
Reported as:
Number · participants
Safety:- Hypersensitivity
participantsBmab1200StelaraStelara-Bmab 1200
Safety:- Hypersensitivity131
Other pre-specifiedImmunogenicity:-Developing Antidrug Antibodies

Proportion of patients developing antidrug antibodies

Time frame:
Baseline through Week 28
Reported as:
Number · participants
Immunogenicity:-Developing Antidrug Antibodies
participantsBmab1200StelaraStelara-Bmab 1200
ADA positive1628886
ADA negative2165
Patients with no post baseline ADA result201
Other pre-specifiedImmunogenicity:-Developing Antidrug Antibodies

Proportion of patients developing antidrug antibodies

Time frame:
Postdosing Week 52
Reported as:
Number · participants
Immunogenicity:-Developing Antidrug Antibodies
participantsBmab1200StelaraStelara-Bmab 1200
ADA positive1317374
ADA negative36810
Patients with no post baseline ADA result100
Other pre-specifiedDeveloping Neutralizing Antibodies

Proportion of patients neutralizing antibodies

Time frame:
Baseline through Week 28
Reported as:
Number · participants
Developing Neutralizing Antibodies
participantsBmab1200StelaraStelara-Bmab 1200
Nab reactive544231
Nab negative1084655
Other pre-specifiedDeveloping Neutralizing Antibodies

Proportion of patients neutralizing antibodies

Time frame:
Postdosing Week 52
Reported as:
Number · participants
Developing Neutralizing Antibodies
participantsBmab1200StelaraStelara-Bmab 1200
Nab reactive271912
Nab negative1045462
Other pre-specifiedPharmacokinetic:-Serum Concentrations

Serum concentrations of ustekinumab

Time frame:
Postdosing on Week 28
Reported as:
Mean · ng/mL
Pharmacokinetic:-Serum Concentrations
ng/mLBmab 1200 (1 Injection)Stelara-Stelara (1 Injection)Stelara-Bmab 1200 (1 Injection)Bmab 1200 (2 Injection)Stelara-Stelara (2 Injection)Stelara-Bmab 1200 ((2 Injection)
Pharmacokinetic:-Serum Concentrations678.308 ± 444.7791589.780 ± 418.9308620.793 ± 398.1352796.833 ± 392.64481070.600 ± 522.0039861.665 ± 549.4014
Other pre-specifiedPharmacokinetic:-Serum Concentrations

Serum concentrations of Ustekinumab

Time frame:
Postdosing on Week 52
Reported as:
Mean · ng/mL
Pharmacokinetic:-Serum Concentrations
ng/mLBmab 1200 (1 Injection)Stelara-Stelara (1 Injection)Stelara-Bmab 1200 (1 Injection)Bmab 1200 (2 Injection)Stelara-Stelara (2 Injection)Stelara-Bmab 1200 (2 Injection)
Pharmacokinetic:-Serum Concentrations728.029 ± 477.1775665.403 ± 379.9506653.908 ± 415.8309881.343 ± 510.00861008.382 ± 671.8667898.450 ± 551.4494
SecondaryPASI Score

Percentage change from baseline in the PASI score at Baseline through Week 52. The PASI (Psoriasis Area and Severity Index) is a score from 0 to 72 that measures psoriasis severity based on lesion redness, thickness, scaling, and body area affected. The body is divided into four regions, each scored separately. Scores are calculated using severity and area involvement, and are used to assess treatment response (e.g., PASI 50 = 50% improvement).

Time frame:
Baseline through Week 52
Reported as:
Mean · Percentage change from Baseline
PASI Score
Percentage change from BaselineBmab1200StelaraStelara-Bmab 1200
PASI Score-95.50 ± 7.507-96.60 ± 5.671-94.71 ± 7.950

Adverse events

Collected over Treatment Emergent Adverse Events (TEAEs) through the Study (Week 52). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bmab12000/191 (0%)6/191 (3.1%)111/191 (58.1%)
Stelara0/101 (0%)0/101 (0%)48/101 (47.5%)
Stelara-Bmab12000/92 (0%)1/92 (1.1%)51/92 (55.4%)
Most frequent serious events
Most frequent serious events
EventBmab1200StelaraStelara-Bmab1200
Cholecystitis acuteHepatobiliary disorders0/1910/1011/92
Squamous cell carcinoma of the tongueNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1910/1010/92
Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1910/1010/92
Acute myocardial infarctionCardiac disorders1/1910/1010/92
Cardiac failureCardiac disorders1/1910/1010/92
Abdominal painGastrointestinal disorders1/1910/1010/92
Jaundice cholestaticHepatobiliary disorders1/1910/1010/92
Uterovaginal prolapseReproductive system and breast disorders1/1910/1010/92
Ischaemic strokeNervous system disorders1/1910/1010/92
Most frequent other events
Showing 10 of 183
Most frequent other events
EventBmab1200StelaraStelara-Bmab1200
NasopharyngitisInfections and infestations18/1916/1018/92
Upper respiratory tract infectionInfections and infestations6/1911/1016/92
Alanine aminotransferase increasedInvestigations12/1916/1012/92
Blood triglycerides increasedInvestigations11/1913/1013/92
InfluenzaInfections and infestations4/1915/1015/92
Aspartate aminotransferase increasedInvestigations7/1912/1010/92
Urinary tract infectionInfections and infestations6/1912/1013/92
COVID-19Infections and infestations4/1910/1013/92
RhinitisInfections and infestations2/1912/1013/92
ProteinuriaRenal and urinary disorders4/1911/1013/92

Baseline characteristics

Patient demographics and baseline characteristics provided on FAS which consist of all participants who signed the ICF and were randomized

Age, Continuous
Age, Continuous(years)Bmab1200StelaraTotal
Mean42.5 ± 13.0943.9 ± 13.5843.2 ± 13.34
Sex: Female, Male
Sex: Female, Male(Participants)Bmab1200StelaraTotal
Female7057127
Male121136257
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Subject)Bmab1200StelaraTotal
Hispanic or Latino6612
Not Hispanic or Latino185187372
American Indian or Alaska Native000
Asian000
Black or African American112
Native Hawaiian or Other Pacific Islander000
White190192382
Other000
Region of Enrollment
Region of Enrollment(Subject)Bmab1200StelaraTotal
Europe189189378
United States246
08

Study locations

1 site
  • Apex Clinical Research Center
    Mayfield Heights, Ohio 44124, United States
09

References and documents

Publications

  • Szepietowski JC, Reich A, Feldman SR, Pulka G, Mekokishvili L, Tsiskarishvili N, Svarca I, Poder A, Singh G, Deodhar S, Kumar K, Marwah A, Loganathan S, Wolff-Holz E, Athalye SN. Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial. Expert Opin Biol Ther. 2025 Oct;25(10):1121-1133. doi: 10.1080/14712598.2025.2576506. Epub 2025 Oct 21. PubMed 41100115 ↗
  • Szepietowski JC, Reich A, Feldman SR, Pulka G, Mekokishvili L, Tsiskarishvili N, Svarca I, Poder A, Singh G, Deodhar S, Kumar K, Marwah A, Loganathan S, Athalye SN, Wolff-Holz E. Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28-week results of the randomized, double-blind, Phase 3 STELLAR-2 study. Expert Opin Biol Ther. 2025 Aug;25(8):913-924. doi: 10.1080/14712598.2025.2538608. Epub 2025 Jul 29. PubMed 40708530 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jan 2023, 6 months.

Results were first posted in Sep 2025, 2 years 7 months after primary completion. A results delay was requested in Nov 2023.

Of 216 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 25. This study's 6 months is below that.

Counting every sponsor, half of 226 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2022
First posted
Apr 19, 2022
StartActual
Jun 28, 2022
Primary completionActual
Jan 26, 2023
CompletionActual
Nov 15, 2023
Results delay requested
Nov 16, 2023
Results first posted
Sep 12, 2025
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05335356
Lead sponsor
Biocon Biologics UK Ltd
Responsible party
Sponsor
First posted
Apr 19, 2022
Start date
Jun 28, 2022
Primary completion
Jan 26, 2023
Completion
Nov 15, 2023
Results posted
Sep 12, 2025
Last update
Sep 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion